Acadia Pharmaceuticals diskutieren
Acadia Pharmaceuticals
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
14,03 €
0,04 %
Buy Acadia Pharmaceuticals
Sell Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at HC Wainwright from $28.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Royal Bank of Canada from $28.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $33.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Royal Bank of Canada from $32.00 to $33.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at Mizuho from a "neutral" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $20.00.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $38.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $42.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $40.00 price target on the stock, up previously from $31.00.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Mizuho from $35.00 to $40.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $37.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $42.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Needham & Company LLC from $37.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Mizuho from $40.00 to $39.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Royal Bank of Canada from $36.00 to $35.00. They now have an "outperform" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $42.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
Neueste Beiträge
Raymond_James in KLA-Tencor Corp. diskutieren